Key facts
- OxyDial’s last known valuation is $8.0M (Mar 2026).
- It has raised $1.9M across 1 recorded rounds; the latest was Seed Round ($700K) in Mar 2026.
- Notable investors include Capital Factory, Ben Franklin Technology Partners of Southeastern Pennsylvania, Science Center.
- OxyDial has filed 1 Form D with the SEC, most recently May 2026 ($700K sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for OxyDial
Funding rounds
1 roundsAbout OxyDial
Developer of oxygen-hemoglobin equilibrium testing instruments intended for research and medical purposes. The company's platform aims to deliver fast, simple, and portable OEC testing, enabling researchers and medical professionals to understand the relationship between blood oxygen and hemoglobin, and diagnose conditions like anemia.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2022
- Employees
- 15
- Website
- oxydial.com/
- Ownership
- Privately Held (backing)
OxyDial doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OxyDial shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OxyDial in its N-PORT filings yet. We sweep new filings monthly.